Uveitis

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

Contrary to prior research, this study indicates that combining tumor necrosis factor inhibitors or another biologic with antimetabolites has a better chance of managing inflammation than any individual medication.

A recent study reveals that glaucoma surgery significantly improves visual outcomes and reduces medication burden in children with uveitic glaucoma.

The recent analysis has indicated the implant’s relative success in maintaining treatment for NIU without need for supplementary treatments.

April sees mixed outcomes in FDA approvals, with promising gene therapies advancing while others face setbacks, highlighting ongoing challenges in ocular treatments.

Parent company VivaVision plans to request a type C meeting with the US Food and Drug Administration.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Study indicates pediatric uveitis can occur independent of autoimmune conditions and dupilumab use

The February 2025 month in review covers 7 key pipeline updates in ophthalmology, including regulatory approvals, label expansions, and topline trial results.

A look back at some of our top coverage in ophthalmology from 2024, including pipeline news and FDA approvals.

TRS01 eye drops demonstrate a positive benefit-risk profile for potential use as a first-line treatment in anterior non-infectious uveitis.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

Both vaccine type and period mediated the risk of uveitis after COVID-19 vaccination in patients with a history of the ocular inflammatory event.

Positive phase 2 results from NEPTUNE represent the best treatment failure rates observed among active studies in non-infectious uveitis.

Patients with uveitis switched from adalimumab originator to SB5 did not experience clinically significant differences in treatment efficacy and safety.

Real-life data reveal the effectiveness of TNF-inhibitor biosimilars in minimizing ocular flares and preserving visual acuity in pediatric patients with uveitis.

A local corticosteroid burst followed by 0.18 mg FAi may be a useful adjuvant for the treatment of noninfectious uveitis, but not sufficient as solo therapy.

Cross-sectional data show an increasing incidence of syphilitic uveitis–related hospitalizations in the US between 2010 and 2019.

In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.

A systematic review and meta-analysis provides insight into the potential for increased risk of noninfectious uveitis among people with vitamin D deficiency.